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Abstract
In human B cells infected with Epstein-Barr virus (EBV), latency-associated virus gene products inhibit expression of the pro-
apoptotic Bcl-2-family member Bim and enhance cell survival. This involves the activities of the EBV nuclear proteins
EBNA3A and EBNA3C and appears to be predominantly directed at regulating Bim mRNA synthesis, although post-
transcriptional regulation of Bim has been reported. Here we show that protein and RNA stability make little or no
contribution to the EBV-associated repression of Bim in latently infected B cells. However, treatment of cells with inhibitors
of histone deacetylase (HDAC) and DNA methyltransferase (DNMT) enzymes indicated that epigenetic mechanisms are
involved in the down-regulation of Bim. This was initially confirmed by chromatin immunoprecipitation analysis of histone
acetylation levels on the Bim promoter. Consistent with this, methylation-specific PCR (MSP) and bisulphite sequencing of
regions within the large CpG island located at the 59 end of Bim revealed significant methylation of CpG dinucleotides in all
EBV-positive, but not EBV-negative B cells examined. Genomic DNA samples exhibiting methylation of the Bim promoter
included extracts from a series of explanted EBV-positive Burkitt’s lymphoma (BL) biopsies. Subsequent analyses of the
histone modification H3K27-Me3 (trimethylation of histone H3 lysine 27) and CpG methylation at loci throughout the Bim
promoter suggest that in EBV-positive B cells repression of Bim is initially associated with this repressive epigenetic histone
mark gradually followed by DNA methylation at CpG dinucleotides. We conclude that latent EBV initiates a chain of events
that leads to epigenetic repression of the tumour suppressor gene Bim in infected B cells and their progeny. This
reprogramming of B cells could have important implications for our understanding of EBV persistence and the pathogenesis
of EBV-associated disease, in particular BL.
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Introduction
EBV is a B lymphotropic gammaherpes virus that asymptom-
atically and persistently infects .90% of humans; it occasionally
causes infectious mononucleosis in adolescents and in rare
instances is associated with the development of several different
types of B cell lymphoma and various epithelial tumours [1]. EBV
can also produce B cell lymphomas in non-human primates and
induce the continuous proliferation (‘immortalisation’) of primary
human B cells in vitro. The lymphoblastoid cell lines (LCLs) that
are produced in culture carry the viral genome as extra-
chromosomal episomes and express only nine ‘latent’ EBV
proteins. There are six nuclear antigens (EBNAs 1, 2, 3A, 3B,
3C & LP) and three membrane associated proteins (LMP1,
LMP2A & 2B); together with several RNA species, these factors
activate the quiescent B cells from G0 into the cell cycle, initiate
and sustain proliferation and maintain the viral episome in its
extra-chromosomal state. Using recombinant viruses it has been
shown that of all the transcripts expressed in LCLs only EBNA1,
2, 3A, 3C, -LP and LMP1 are essential for the efficient
transformation of primary B cells into LCLs (reviewed in [2]).
Current data on the normal asymptomatic persistence of EBV
in humans are consistent with the viral genome residing long-term
in a resting memory B cell population. However, in order to
establish persistence, EBV infects non-dividing naı¨ve B cells and
drives these to proliferate as activated B blasts that express all the
viral proteins found in LCLs. The transient expansion of an
infected B blast population is accompanied by their differentiation,
probably in germinal centres, to become centroblasts and
centrocytes and finally resting memory B cells. The precise series
of events that the EBV-positive B cells undergo to reach the
memory compartment is not yet known. However, it appears to
involve the regulated shut-down and silencing of latent EBV gene
expression from an initial state called latency III or the growth
programme (as found in LCLs), via latency II (also known as the
default programme), until in quiescent memory B cells no EBV
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proteins can be detected in a state called latency 0 (or the latency
programme) (reviewed in [3]).
Using recombinant viruses established with a bacterial artificial
chromosome (BAC) system, we recently showed that EBNA3A
and EBNA3C are both necessary for repression of the cellular
gene Bim [4]. The Bim protein (Bcl-2 interacting mediator of cell
death) is a pro-apoptotic BH3-only, Bcl-2-family member that
appears to be a uniquely important tumour suppressor in the
development of B and T lymphocytes. It regulates apoptosis
during lymphocyte development by binding and inactivating pro-
survival members of the Bcl-2 family and binding and activating
the pro-apoptotic family member Bax (reviewed in [5,6]). The role
of Bim in lymphomagenesis came sharply into focus when it was
discovered that in Em-Myc transgenic mice constitutively express-
ing Myc in B cells, loss of even a single Bim allele significantly
accelerated lymphoma development and revealed Bim as a
haploinsufficient tumor suppressor [7]. Deregulation of Myc
through reciprocal chromosome translocations that put the gene
under the influence of immunoglobulin locus control elements is a
hallmark of all BLs (reviewed in [8,9]). The importance of Bim in a
cell carrying a deregulated Myc became apparent when it was
discovered that under these conditions combined activation of
both the ARF/p53 pathway and Bim leads to apoptosis [10].
However, when Myc is mutated or either the activation of ARF/
p53 or Bim is impaired, the result is B lymphomagenesis [10,11].
The clear implication is that if EBV inhibits an increase in Bim
expression when wild-type Myc is deregulated by translocation, this
could be a mechanism through which EBV directly contributes to
the development of BL.
Since during latency III, EBNA2 constitutively activates Myc, this
repression of Bim expression is probably critical for the immorta-
lisation of B cells by EBV, persistence in vivo and perhaps the
development of the endemic EBV-positive form of BL [4,12] – it is
therefore central to EBV biology. However the details of how Bim
levels are modulated by EBV is a controversial subject since it has
been reported that EBV can alter both Bim gene expression and Bim
protein stability [4,13]. Here the molecular mechanism by which
EBV regulates the amount of Bim has been explored further and
this has revealed that heritable, epigenetic modifications in the 59
regulatory region of Bim play a major role in determining the level of
Bim protein expressed in EBV infected B cells.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The samples for this study were
obtained from the archives of the VU University medical centre.
These were collected during 1996–2007 as part of collaborative
studies in Malawi and Uganda on the diagnosis of Epstein-Barr
virus associated malignancies. Written, informed consent was
obtained from the guardians of study participants at the time of
collection.
Cell culture
All B cell lines were cultured in RPMI-1640 medium
(Invitrogen) supplemented with 10% fetal calf serum, penicillin,
streptomycin, 1 mM sodium pyruvate (Sigma) and 50 mM a-
thioglycerol (Sigma). 100 mg/ml hygromycin B (Roche) was added
to cultures of BL containing recombinant hygromycin- resistant
EBV (BL31 WT, BL31 E2KO), as described in [4]. All other cell
lines used in this study were described previously in [14,15,16].
24 hours before any experimental treatment, cells were seeded at a
density of 2.56105 cells/ml.
Cell treatments
MG-132 (Calbiochem) was used at a final concentration of
5 mM, 10 mM or 15 mM. Actinomycin D (Sigma) was used at a
final concentration of 5 mg/ml. Trichostatin A (TSA), 5-azacyti-
dine (AZA) and sodium butyrate were all purchased from Sigma
and were used at concentrations of 500 nM, 5 mM and 2.5 mM
respectively.
Western immunoblotting
Western immunoblotting was performed as described previously
[4,15,17]. Primary antibodies used for western blot probing were:
rabbit polyclonal anti-Bim/BOD (Stressgen, AAP-330), mouse
monoclonal anti-p21WAF1 (SX118, kind gift from Prof. Lu Xin,
Ludwig Institute, Oxford), mouse monoclonal anti-c-tubulin
(Sigma, T6557), mouse monoclonal anti-BZLF1 (kind gift from
Prof. Paul Farrell, Imperial College London), sheep polyclonal anti-
EBNA3A (Exalpha, USA), mouse monoclonal anti-EBNA3C (A10,
kind gift from Prof. Martin Rowe, University of Birmingham).
Quantitative reverse transcriptase real time PCR (Q RT-
PCR)
For Q RT-PCR, RNA was extracted from approximately 56106
cells for each cell line using the RNeasy mini kit from Qiagen and
following the manufacturer’s instructions. To quantify BimEL mRNA
after HDAC and DNMT inhibitors treatment, 25 ng of RNA were
used for each reaction with one-step QuantiTect SYBR green RT-
PCR kit from Qiagen and ABI PRISM 7700 Sequence Detector,
according to the manufacturer’s instructions. BimEL primers were
GCTGTCTCGATCCTCCAGTG and GTTAAACTCGTCTC-
CAATACG as described previously [4]. GAPDH was used to
normalize BimEL levels. GAPDH primers were purchased from
Qiagen (Hs_GAPDH_2_SG; QT01192646). The PCR conditions
were 30 min at 50uC, 15 min at 95uC and then 30 sec at 95uC,
30 sec at 58uC and 30 sec at 72uC for 40 cycles. The standard curve
Author Summary
Bim is a cellular inducer of programmed cell death (pcd),
so the level of Bim is a critical regulator of lymphocyte
survival and reduced expression enhances lymphomagen-
esis in mice and humans. Regulation of Bim is uniquely
important in the pathogenesis of Burkitt’s lymphoma (BL),
since in this human childhood cancer the Myc gene is
deregulated by chromosomal translocation and Myc can
induce pcd via Bim. Latent EBV represses Bim expression,
and here we have discovered that this involves mecha-
nisms that reprogramme B cells and their progeny. EBV
does not significantly alter Bim protein or RNA stability,
but relief of EBV-mediated repression by specific inhibitors
suggested it involves modifications to chromatin. Consis-
tent with this, reduced histone acetylation and increased
levels of DNA methylation on the Bim promoter were
found after latent EBV infection. Further analysis suggested
that the DNA methylation is preceded by repression
mediated via a polycomb protein repressive complex
targeting the Bim gene. By initiating the heritable
suppression of Bim, EBV increases the likelihood of B
lymphomagenesis in general and BL in particular. This
reprogramming of B cells by EBV may also play a role in
the development of other chronic disorders such as
autoimmune disease and suggests a general mechanism
that could contribute to the pathogenesis associated with
other microorganisms.
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method was used. Standards were a mix of all RNAs used and five 10-
fold serial dilutions of this.
For quantification of mRNA after actinomycin D treatment, 5 ng
of RNA were used for each reaction with one-step QuantiTect SYBR
green RT-PCR kit from Qiagen and ABI PRISM 7900 Sequence
Detector, according to the manufacturers’ instructions. The same
primers as above were used for BimEL. For Myc the primers were
AGCTGCTTAGACGCTGGATTT and GAGGTCATAGTT-
CCTGTTGGTGAA and for b-Actin they were GATGGAGTT-
GAAGGTAGTTTCGTG and GCGGGAAATCGTGCGTGA-
CATT [18]. Reaction conditions were the same as above. The
calculated errors in the graphs are the standard deviations from three
replicate Q RT-PCR reactions for each mRNA.
Chromatin immunoprecipitations (ChIP)
Chromatin Immunoprecipitation Assay Kit from Upstate (17-
295) was used, according to the manufacturer’s protocol. To
obtain sheared chromatin with DNA of 200 bp–1000 bp in
length, extracted chromatin from 16106 cells per ChIP was
sonicated in 200 ml lysis buffer for four 20 sec sonication rounds,
using a Heat Systems Sonicator Ultrasonic Processor XL at 10%
intensity.
The antibodies for the acetylated histones IPs were rabbit
polyclonal IgG anti-acetyl-Histone H3 (Upstate; 06-599), rabbit
polyclonal IgG anti-acetyl-Histone H4 (Upstate; 06-866) and as a
negative control Rabbit IgG serum (Upstate; PP64). Precipitated
DNA was assayed by quantitative PCR (Q-PCR) using Qiagen’s
QuantiTect SYBR green PCR kit. 2% of input was compared to the
IP sample and the values from the IgG negative control were
subtracted as background. Primers for Bim were CTGGTC-
TGCAGTTTGTTGGA and GGTGGCTGCAAGAATCAAGT.
b-Actin was used as an independent control. b-Actin primers were
TGCACTGTGCGGCGAAGC and TCGAGCCATAAAAGG-
CAA [19]. The PCR conditions were 15 mim at 95uC and then
20 sec at 95uC, 30 sec at 55uC, 30 sec at 72uC for 40 cycles, using
ABI PRISM 7700 Sequence Detector.
ChIP for histone H3 trimethylated at K27 was performed as
described above, using anti-H3K27-Me3 antibody from Upstate (17-
625) and as a negative control Rabbit IgG serum (Upstate; PP64).
The primers used to quantify precipitated DNA were: pair A:
TTTAGAAAGAATCTTGGCAGTCAACTCCTC and CAAT-
GGCTGGTGAAAAGGAGGGTTT, pair B: GAAGGACCAGG-
GAGGAAGGACCAAG and TGACACCTAGCCCAGTGGAA-
ACCCC, pair C: CGAGCGGGAAAAAAGGTTTGGTTCA and
TAGGCTCCCACTTCCTTCTCCCAGT, pair D: AAGAG-
CAAAGTTCGTCCGCGGTAGG and TATTTCGCTGCAA-
GAGGGAAAAGGCAC, pair E: GACCCTCAGAGGGAGGA-
GAGCTCAAA and GCCCTGAGTTTCTAAGCCGCTCTGG,
pair F: CGCCAGCAGGCAGAGTTAC and CAGGCTCGGA-
CAGGTAAAGG. The cycling conditions were 2 min at 50uC,
10 min at 95uC and then 15 sec at 95uC, 1 min at 60uC for 40 cycles,
using ABI 7900 384-well Real-Time PCR machine. The calculated
errors in all graphs presenting ChIP data are the standard deviations
from three replicate Q-PCR reactions for precipitated chromatin,
input chromatin and background (chromatin precipitated with non-
specific rabbit IgG).
Methylation specific PCR (MSP) and bisulphite
sequencing
For the methylated DNA control, in vitro methylated Jurkat DNA
was used (Active Motif, 102163). B cells were isolated from a buffy
coat residue purchased from the blood transfusion service, using the
AutoMACS 3 sorting system from Millitenyi Biotec. CD19 positive
selection, with the CD19 MicroBeads from the same manufacturer
(130-050-301), was performed according to their instructions. PBMC
genomic DNA was extracted from blood of a healthy donor.
Genomic DNA was extracted with the Qiagen DNeasy Kit for all the
cells described. 200–500 ng of genomic DNA was converted by
bisulphite using EZ DNA methylation kit by Zymo Research
(D5002). For MSP the converted DNA was amplified using 5 sets of
primers, specific for 5 different regions of the Bim promoter. The
sequences were – For Set I: U2F: GTTTTGGGGTTTTGTAAG-
GAAAT; U2R: AAATAATAAAAATATTTTCCACACC; M2F:
TTTTGGGGTTTTGTAAGGAAAC; M2R: TCAAATAA-
TAAAAATATTTTCCGCG. For Set II: U3F: GGTTTA-
GTTTTGGGAGGATTTTTT; U3R: ACCAAAAATAACA-
AATTCATACATC; M3F: GTTTAGTTTCGGGAGGATT-
TTTC; M3R: ACCAAAAATAACGAATTCATACGTC. For Set
III: U4F: TTTTTGAGTTTATTTAGTTGTGTTTATGT; U4R:
AAAACCTTAAATTCCCAAAATCACT; M4F: CGAGTT-
TATTTAGTCGTGTTTACGT; M4R: CTTAAATTCCC-
GAAATCGCT. For Set IV: U1F: TGTTTAAAATTTATTT-
GAAAATGTGT; U1R: ACAAATAAAAAAACATTATCCC-
ACC; M1F: TCGTTTAAAATTTATTCGAAAATGC; M1R:
AACAAATAAAAAAACGTTATCCCG. For Set V: U5F: GTA-
GATTTAGAGGATTGGAGAGGTG; U5R: ACCAATAAAAA-
CAAAACAACTAAATTCA; M5F: GTAGATTTAGAGGATTG-
GAGAGGC; M5R: CAATAAAAACAAAACAACTAAATTCGA.
For bisulphite sequencing primers AAAACCCCCAAAATT-
TACTAAACTC and GGGAATTTAAGGTTTTTTTTATTT
were used to amplify a region of the Bim promoter (see below), in
order to sequence and study the methylation state of 36 CpG
dinucleotides in this region. The amplified PCR products were
cloned using the Invitrogen TA cloning kit. Plasmids containing
the cloned sequences were amplified by rolling circle amplification
(Templiphi; GE healthcare) and sequenced. Between 8 and 24
clones were sequenced for each cell line.
BL biopsy samples
Frozen tissue was collected in parallel with routine biopsy
specimens from suspected BL-cases at the Uganda Cancer
Institute by Dr. J.Orem (Makarere University, Kampala, Uganda)
and were retrieved from the archives of Dept. Pathology, VU
University medical centre in Amsterdam, The Netherlands. All
biopsies were classified by routine cytology on paraffin-embedded
formalin-fixed tissue and EBER-RISH using PNA probes (DAKO,
Glostrup, Denmark) [20].
Precipitation of methylated DNA with His-tagged MBD2b
After isolating genomic DNA as described above, 2 mg of
DNA was sonicated in 200 ml of H2O for five 20 sec sonication
rounds, using a Heat Systems Sonicator Ultrasonic Processor XL
at 10% intensity, to produce sheared DNA with length of 200–
1000 bp. Methylated DNA was precipitated from 1 mg of
sheared DNA using the MethylCollector kit (Active Motif,
55002) according to the manufacturer’s instructions. Precipitated
DNA was quantified in exactly the same way as described for
the ChIP for H3K27-Me3, with the same primer pairs (A–F),
the same quantitative PCR conditions and the same method of
analysis. As background control, precipitations with just the
magnetic beads were performed, without addition of His-
MBD2b. As additional controls, precipitations were performed
using DNA from PBMCs (unmethylated) and Jurkat DNA (fully
methylated in vitro). The calculated errors in all graphs presenting
methylated DNA precipitation data are the standard deviations
from three replicate Q-PCR reactions for precipitated DNA and
input DNA.
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Results
Latent EBV does not suppress Bim protein levels by
enhancing proteasome-mediated proteolysis or reducing
Bim mRNA stability
It has been reported that EBV reduces Bim expression by
targeting it to the proteasome system for degradation [13]. Since
EBV induces the phosphorylation of extracellular signal regulated
kinase (ERK) and this activated form of ERK can phosphorylate
Bim and mark it for ubiquitinylation, it was suggested that latent
EBV enhances Bim turnover by proteasomes. However, we
recently showed that inhibition of ERK phosphorylation in EBV-
positive BL cells does not necessarily result in significantly higher
levels of Bim, but that in EBV-positive cells Bim mRNA was
always substantially reduced [4]. Nevertheless, this does not
exclude the possibility that Bim protein is degraded by the
proteasome system via another signalling pathway. In order to
investigate this in more detail, EBV-negative BL31 cells, BL31
cells infected with a wild type (B95.8 strain) EBV-BAC (BL31 WT)
and BL31 infected with an EBV-BAC with EBNA2 deleted (BL31
E2KO) were treated with the inhibitor of proteasome function,
MG-132. Western blots in Figure 1A show that the addition of
increasing amounts of MG-132 had no significant effect on the
expression of the major Bim isoform BimEL after eight hours. The
same was true after twenty-four hours of treatment, however at
this time there was considerable cell death (data not shown).
Under the same conditions p21WAF1 – a protein with a relatively
short half-life because it is rapidly degraded by proteasomes
[21,22] – accumulated, thus demonstrating that the MG-132
successfully inhibited proteosome-mediated proteolysis. It is
unlikely therefore that enhanced protein degradation is the main
cause of the lower levels of Bim seen in B cells containing latent
EBV. Although latent EBV gene expression can alter ERK
signalling and may therefore affect Bim by phosphorylation and
ubiquitinylation, our data are consistent with EBV primarily
inhibiting the de novo synthesis of Bim, rather than enhancing its
turnover.
Recently it was shown that Bim levels are also regulated by
modulation of Bim mRNA stability [23]. It is therefore
conceivable that EBV reduces the stability of Bim mRNA, leading
to lower steady-state levels of Bim transcripts and protein in
infected cells. To examine this possibility, the same BL31 cell lines
were treated with the inhibitor of transcription actinomycin D for
up to eight hours to block de novo synthesis of RNA. BimEL mRNA
was then analysed by quantitative (Q) RT-PCR to assess whether
in EBV infected cells BimEL mRNA was degraded more rapidly
(Figure 1B). Although, as expected, the starting levels of Bim
mRNA were different in each cell line (see histogram in Figure 1B),
in each cell line the mRNA levels dropped, showing that
transcription was successfully inhibited. Moreover, the rate of
BimEL mRNA degradation was very similar in EBV infected and
uninfected cells indicating that the presence of latent EBV does not
significantly influence BimEL mRNA stability. In parallel, the
stability of an mRNA known to have a short half-life (Myc) and
one known to be very stable (b-Actin) were assessed (Figure S1).
The data from these experiments using inhibitors of either
proteosome enzymes or mRNA synthesis are therefore most
consistent with the regulation of Bim expression occurring principally
at the level of transcription as we previously suggested [4].
Inhibitors of HDACs and DNMTs increase BimEL protein
and mRNA levels in EBV infected cells
In the absence of evidence supporting an alternative mechanism
for Bim regulation by EBV, we investigated whether latent EBV
Figure 1. Down-regulation of Bim in EBV-positive cells is not
due to proteosomal degradation or decreased mRNA stability.
A) Uninfected EBV-negative BL31 cells, or BL31 cells infected with a wild
type (B95.8 strain) EBV-BAC (BL31 WT), or BL31 infected with an EBV-
BAC carrying a deletion of the EBNA2 gene (BL31 E2KO) were treated
with the proteasome inhibitor MG-132 for 8 hours at the concentrations
indicated. Protein levels were assessed by western immunoblotting.
p21WAF1 protein was used as a control and its accumulation after
treatment in all cells indicates that proteasome-mediated degradation
is inhibited. BimEL levels are unaffected and remain low in EBV infected
cells. B) The same panel of cells was treated with the inhibitor of
transcription actinomycin D (5 mg/ml) for 8 hours. BimEL mRNA levels
were measured by quantitative RT-PCR, using constant amounts of total
RNA for each time point, and are shown in the graph relative to the
starting Bim mRNA levels. The amounts of BimEL mRNA at the
beginning of the treatment, relative to the levels in uninfected cells,
are shown on the column graph at the bottom. The rate of mRNA
degradation is similar in all three cell-lines.
doi:10.1371/journal.ppat.1000492.g001
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could influence transcription of Bim via the modification of local
chromatin. There are several reports of Bim expression being
regulated by modulation of transcription (for examples see
[24,25,26]) and a striking feature of the gene is an unusually
large CpG island of more than 6000 bp extending either side of
the transcription initiation site (http://genome.ucsc.edu/cgi-bin/
hgGateway; Figure 2); this region could be subject to control by
DNA methylation. Since both histone deacetylation and DNA
methylation are associated with repressed, inactive chromatin,
these were investigated initially using chemical inhibitors (reviewed
in [27,28,29]).
To get an indication of whether the regulation of Bim
transcription might involve local chromatin or DNA modifications
BL31, BL31 WT, and LCL-CH cells were treated with the HDAC
inhibitor trichostatin A (TSA), the DNMT inhibitor 59 azacytidine
(AZA) or with sodium butyrate – which is reported to suppress
HDACs and might affect DNA methylation [30,31]. Cells were
treated with one of the inhibitors and samples were taken after 24
and 48 hours. The levels of BimEL protein following these
treatments can be seen in western blots (Figure 3A). Exposure of
EBV-positive BL31 WT cells to TSA resulted in a significant up-
regulation of BimEL levels, but in uninfected BL31 cells the already
high level remained unchanged. In the LCL cells up-regulation
was more pronounced – even after 24 hours of treatment. AZA
had more moderate effects on BimEL protein levels, with little
change in the LCL, but significant up-regulation in BL31 WT.
Exposure of both BL31 WT and the LCL to sodium butyrate
produced the most substantial increase of BimEL. Two other EBV
negative/positive ‘‘pairs’’ of BL cell lines, BL41/BL41 B95.8 and
Ramos/Ramos-AW together with two BL-derived cell lines Eli
and Akata 6, were treated in a similar way and these showed the
same trend of BimEL up-regulation as described above (Figure S2A
and B). Since both TSA and AZA have been shown to induce the
lytic cycle in EBV infected cells [32,33], western blots were
performed to determine whether the EBV lytic switch protein
BZLF1 was induced. No correlation between lytic cycle and Bim
expression was detected in these cells (Figure S2C). This is
consistent with our previous observations [16].
Subsequently the amount of BimEL mRNA in cells harvested
after similar treatments was assessed by real-time Q RT-PCR
(Figure 3B). This analysis was performed on samples taken
48 hours after the addition of the inhibitor. BimEL sequences were
amplified using primers described previously [4]. Values for BimEL
mRNA were normalized to values obtained for GAPDH primers.
Quantification used standard curves for each pair of primers,
always using the same standards. Similar trends of BimEL up-
regulation were seen at the mRNA level (Figure 3B) as at the
protein level (Figure 3A), indicating that latent EBV is associated
with repression of Bim transcription via mechanisms involving
both histone deacetylation and DNA methylation. An exception
was LCL-CH in which the up-regulation of Bim mRNA by 5-
azacytidine was significantly greater than the amount of protein
induced. We do not know the reason for this discrepancy, but it
should be noted that all three inhibitors were very toxic in the cells
used here, inducing a great deal of cell death and so making these
experiments rather unsatisfactory. Nevertheless the results were
each largely consistent with the hypothesis that EBV repression of
Bim involves local chromatin modifications.
EBV reduces acetylation of histones occupying the Bim
promoter
Since Bim levels can be increased in EBV infected cells by
treatment with HDAC inhibitors, it seems likely that EBV regulates
Bim, at least in part, through the modulation of histone acetylation.
If the effect is direct, this means that in the presence of EBV,
histones associated with the Bim promoter should be less acetylated
relative to uninfected cells. To directly assess occupancy of the Bim
promoter by acetylated histones, chromatin immunoprecipitations
(ChIPs) were performed using antibodies directed against acetylated
histone H3 (K9Ac, K14Ac) and acetylated histone H4 (K4Ac,
K7Ac, K11Ac, K15Ac). The results are shown in Figure 4. Real-
time Q PCR was used to measure the abundance of a DNA
Figure 2. Schematic of the Bim promoter and CpG-island. The Bim 59 regulatory region has a very large CpG-island that could be subject to
transcriptional control. The predicted CpG-island is 6718 bp long and contains 595 CpG dinucleotides. The regions amplified by PCR for chromatin
immunoprecipitation analysis [ChIP, (A–F)] and methylation specific PCR [MSP, (I–V)] and the region sequenced after bisulphite conversion (bisulphite
sequencing) are shown, with their positions relative to the transcription initiation site indicated. The locations of the predicted transcription initiation
site and start codon are indicated [54].
doi:10.1371/journal.ppat.1000492.g002
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fragment from the Bim promoter that was associated with
immunoprecipitated histones. The primers used correspond to a
region just downstream of the transcriptional start site (shown in
Figure 2). Acetylated histone occupancy of the b-Actin promoter was
measured as a control. Values for each immunoprecipitation were
normalized to 2% of input DNA, and in each case the values
obtained from the control sample incubated with rabbit pre-
immune IgG were subtracted as background. Two EBV-negative
BL lines were used, BL31 and BL41, and their EBV-positive
counterparts, BL31 WT and BL41 B95.8. It is clear that EBV
significantly decreases acetylated histone (H3 and H4) occupancy in
both EBV positive lines, relative to the uninfected ones. Histone
acetylation on the b-Actin promoter was largely unaffected by EBV,
indicating that the effect on Bim is specific. The data are consistent
with EBV inhibiting Bim transcription by the direct modulation of
biochemical marks on chromatin of the Bim promoter.
Latent EBV increases DNA methylation of the Bim
promoter
DNA methylation is associated with inactive chromatin and the
repression of transcription [27,28,29,34]. The observation that
treatment of some EBV-infected B cells with the DNMT inhibitor
59 azacytidine led to the de-repression of Bim, and the presence of
a remarkably large CpG island spanning the 59 regulatory region
of Bim, led us to investigate the DNA methylation status of the Bim
promoter region. In order to discover whether EBV directly
influenced DNA methylation patterns on the promoter we used
methylation specific PCR (MSP) and bisulphite sequencing
directed at various sites upstream of the transcription initiation
site (see schematic in Figure 2). For the initial analysis, twenty-six
cell lines (plus primary cells) were investigated by MSP and of
these, twenty were studied further using bisulphite sequencing to
determine the DNA methylation state of Bim relative to their EBV
status (ie EBV-positive or -negative). The EBV-negative cells used
were either primary cells [peripheral blood mononuclear cells
(PBMCs) or purified CD19+ primary B cells] or EBV-negative BL
cell lines. The EBV-positive cell lines were LCLs (early passage or
late passage), in vitro BL ‘converts’ (that is BL lines established from
EBV-negative tumours and then infected in vitro with EBV), or BL
lines established from EBV-positive tumours.
For the MSP analysis five sites were tested with primer sets (I–V)
of two primer pairs specific for either methylated or unmethylated
DNA. The regions of the Bim promoter amplified by the MSP
Figure 3. Bim expression can be up-regulated in EBV infected cells after treatment with HDAC or DNMT inhibitors. A) EBV-negative
BL31, EBV-positive BL31 WT and LCL-CH were treated with TSA (500 nM), 59 azacytidine (AZA; 4 mM) or sodium butyrate (Na But; 2.5 mM) for up to
48 hours. BimEL protein levels were assessed by western immunoblotting. B) After similar treatments BimEL mRNA levels were measured by
quantitative RT-PCR. BimEL mRNA levels were all normalized with GAPDH mRNA levels. The values over the columns indicate their height, which
represents abundance of Bim mRNA relative to the standards used, after normalization with GAPDH mRNA levels.
doi:10.1371/journal.ppat.1000492.g003
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primers are indicated in Figure 2. The results are summarized in
the matrix shown in Figure 5. Cell lines that gave a band with any
of the methylation-specific primers were scored as methylated (M).
Cell lines that only gave a band with primers for unmethylated
DNA, and none with primers for methylated DNA were scored as
unmethylated (U). These analyses were generally performed at
least three times and an example of representative primary data
for twenty cell lines plus primary cells using primer set III can be
seen in Figure S3.
In PBMCs and purified primary B cells Bim was always
completely unmethylated in these assays – as would usually be
expected of a CpG-island associated with an active gene and
protected by transcription factors from DNA methylation [34].
Similarly, all the established EBV-negative BL lines (that had all
been cultured on and off for decades) were found to be
unmethylated at these sites, with the exception of Ramos, which
gave a faint band for methylation only with primer set III. In
contrast, all late passage LCLs that have also been cultured for
many years, showed methylation at nearly all these sites. One of
the early passage LCLs (LCL-CH, recently established in our lab
by the infection of CD19+ B cells with B95.8 strain of EBV [15]
and only grown continuously in culture for 2–3 months before
being frozen) was found to be unmethylated. EBV-positive in vitro
BL converts gave a mixed picture, with two being methylated and
one unmethylated. In contrast, all the BL lines established from
EBV-positive tumours were methylated at two or more sites on the
Bim promoter. This group included four BL cell lines exhibiting a
latency I pattern of EBV gene expression. These latency I cells do
not express EBNA3A or EBNA3C, the viral proteins that appear
to be necessary for the initial down-regulation of Bim. This
strongly suggests that DNA methylation of the Bim promoter is a
secondary epigenetic effect of latent EBV infection and may be
triggered in BL progenitor cells (for a more detailed and
considered discussion of this point see below).
Bisulphite sequencing was used for a more comprehensive
investigation of the CpG methylation pattern on the Bim promoter
of twenty-one cell lines plus the PBMCs. After bisulphite
modification, a region of 565 bp was subjected to DNA sequence
analysis and the 36 CpG dinucleotides were scored for their
methylation state. An average of 12 and a minimum of 8 clones
were sequenced for each cell type. The results presented in Figure 6
give a detailed ‘‘snapshot’’ of the DNA methylation state of a
significant region of the Bim promoter and CpG-island. The data
are largely consistent with and extend the MSP data that are
summarized in Figure 5. PBMCs and all the EBV-negative BL
lines are essentially unmethylated across this region of the Bim
promoter. In contrast to these EBV-negative cells, all the EBV-
positive cell lines show a significantly higher frequency of
Figure 4. Latent EBV decreases occupancy of acetylated histone-H3 and histone-H4 on the Bim promoter. ChIPs were performed on
EBV-negative BLs (BL31 and BL41) and BLs infected with a wild type EBV-BAC (BL31 WT) or virus (BL41 B95.8), using antibodies against acetylated
histone H3 (K9Ac, K14Ac) and acetylated histone H4 (K4Ac, K7Ac, K11Ac, K15Ac). Immunoprecipitated DNA, associated with acetylated histones, was
assayed by quantitative PCR and expressed in the graphs as fold enrichment relative to input chromatin. Changes are specific to Bim, since occupancy
of acetylated histones on the Bim promoter decreases significantly in EBV-infected cells (upper panels). Occupancy of b-Actin promoter does not
change significantly whether or not the cells carry EBV (lower panels).
doi:10.1371/journal.ppat.1000492.g004
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methylated CpGs. Nevertheless, again the BLs infected with EBV
in vitro and early passage LCLs are generally less methylated than
late passage LCLs and all the EBV-positive BL lines derived
from EBV-positive tumours. These and the MSP data are
consistent with epigenetic repression via chromatin modification
preceding DNA methylation as has been described previously for
other genes [35,36]. Included in the series that were subjected to
bisulphite sequencing was a sub-clone of Akata BL (Akata 31
[37]) that has lost the EBV episome in culture and therefore
expresses no EBV factors. The Bim promoter in Akata 31
appears to be almost as methylated on CpG dinucleotides as the
EBV-positive clone Akata 6, indicating that – once it is
established – DNA methylation of this locus does not require
EBV for its maintenance.
Methylation of the Bim promoter in BL biopsy samples
The same MSP primer sets used for all the B cell lines shown
above were used to test the methylation state of the Bim promoter
in DNA extracted from 14 randomly selected African BL biopsy
samples (summarized in Figure 7). All these samples were isolated
from patients with suspected BL and confirmed as true BL by
routine pathological examination (monomorphic lymphoma with
starry-sky macrophages) and a positive reaction by EBER-RISH,
reflecting EBV presence in the tumour cells (see Figure 8A for two
representative examples). DNAs isolated from purified CD19+
primary B cells and PBMCs were used as negative controls. As
might be expected from biopsy-derived material, the results are
rather heterogenous. Nevertheless the vast majority of BL (13/14)
showed some evidence of Bim promoter DNA methylation by
MSP. The only biopsy scoring completely negative was one that
histopathology identified as including a large epithelial field, so the
amount of BL-derived DNA from this sample is uncertain. Again
the primary B cells, PBMC and in addition two EBV-negative
lymphoid samples were totally negative for DNA methylation.
DNA from two samples (9 and 27) was used for bisulphite
sequencing and the results – together with EBER staining and
MSP analysis – are shown in Figure 8. The level of methylation
across the 565 bp stretch of sequenced DNA appears to be non-
random, and at several loci 70–100% of the clones sequenced were
positive for CpG methylation.
From all the biopsy samples, amplification products were also
apparent with primers specific for unmethylated DNA (eg
Figure 8B and Figure S4). This may be because in some of these
rapidly proliferating tumours, at the time of harvesting, cells had
just replicated their DNA and methylation was not established on
the newly formed DNA strand. Alternatively, the unmethylated
DNA could be the result of non-BL cells in the samples resulting
from infiltration into the tumour or contamination during isolation
of the biopsy samples. Nevertheless, the presence of amplification
products with primers specific for the methylated state in most
EBV-positive BL but not EBV-negative cells is consistent with the
hypothesis that CpG methylation of Bim can occur during the
pathogenesis of EBV-positive BL and is directed by EBV in some
unidentified way.
EBV increases trimethylation of histone H3 lysine 27
(H3K27-Me3) at the Bim promoter
The results of the DNA methylation studies on EBV-positive
and -negative B cells suggested that CpG methylation was
probably not the primary event in the suppression of Bim
transcription by EBV. Specifically, early passage LCLs and
EBV-negative BL cells newly converted by EBV infection in vitro
have a reduced level of Bim (protein and transcripts) but show only
very modest amounts of DNA methylation. In contrast late
passage LCLs and BL cell lines derived from EBV-positive
tumours have relatively high levels of DNA methylation that is
non-randomly distributed on the Bim promoter.
Since in cell transformation and oncogenesis, methylation of
DNA is often preceded by trimethylation of lysine 27 on histone H3
(H3K27-Me3, [38,39,40,41], reviewed [42]), we asked whether
Figure 5. MSP analysis of the Bim promoter in EBV-negative
and EBV-positive cells. Five different sets of methylation specific
primers were used for five different regions of the Bim promoter. In the
matrix presented, the DNA methylation state assessed with the MSP
primers is indicated for each primer set used. When an amplification
product was apparent with the primers specific for unmethylated DNA,
but not with the primers specific for methylated DNA of the same
region, the cell line was scored as unmethylated (U in colourless boxes)
at the regions the MSP primers anneal. When an amplification product
was apparent with the primers specific for methylated DNA the cell line
was scored as methylated (M in red boxes), for the relevant regions. X
indicates that MSP was not performed with this primer set on this
sample. DNA isolated from peripheral blood mononuclear cells (PBMC)
and purified primary B cells was used as control for unmethylated DNA.
In vitro methylated DNA from Jurkat cells was used as control for
methylated DNA (Meth).
doi:10.1371/journal.ppat.1000492.g005
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there were differences in this epigenetic chromatin mark on the Bim
promoter in EBV-positive compared to EBV-negative B cells. Using
the same two pairs of cell lines used for the histone acetylation
ChIPs shown in Figure 4 and an essentially similar ChIP assay, but
using mAbs directed against H3K27-Me3, the distribution of this
mark across the Bim promoter was determined. The results shown in
Figure 9 are consistent with the hypothesis that EBV targets Bim for
repression via the methylation of H3K27. Using six sets of primer
pairs (indicated as A–F in Figure 2) for amplification and real-time
Q PCR analysis of various loci in the Bim promoter/CpG-island, it
is clear that latent infection of both BL31 and BL41 with EBV is
accompanied by a significant increase in H3K27-Me3 throughout
most of the region. For reasons that are unknown the only primers
sets that did not produce this differential effect were E and F when
used on BL41 cells.
Comparison of H3K27-Me3 and DNA methylation profiles
throughout the Bim promoter
In order to obtain greater insight into the relationship between
H3K27-Me3 and CpG methylation at specific sites across the Bim
promoter, we utilized a quantitative assay that depends on the
precipitation of methylated DNA fragments by a histidine-tagged
methyl-CpG-binding domain (MBD) protein (MBD2b). Using this
technology it was possible to quantify the overall level of CpG
methylation on the DNA fragments amplified by primers A–F
Figure 6. Bisulphite sequence analysis of the Bim promoter from cell lines. A region of 565 bp was sequenced and 36 CpGs were scored
within this for their methylation state. An average of 12 clones for each cell line were analysed. The position of the bars on the X-axis within each box
exactly corresponds to the position of the CpG in the sequenced region. The height of the bars reflects the percentage of sequenced clones found to
have a methylated cytosine at that particular CpG dinucleotide. If the bar reaches the top of the box all clones were methylated at the particular CpG
(100%). All EBV-positive cell lines appear to be significantly more methylated than all the EBV-negative cells. EBV-positive cell lines shown include in
vitro converts, early and late passage LCLs and tumour-derived cell lines with either latency III or latency I patterns of EBV expression. In the bottom
right panel results for Akata 31 are shown, a cell line that was derived from a culture of latency I Akata, but that has lost the EBV episome.
doi:10.1371/journal.ppat.1000492.g006
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(Figure 2 and 9) and in parallel measure the overall level of
H3K27-Me3 at the same loci (see schematic in Figure 10A). These
analyses were performed on BL41 and its EBV-positive equivalent,
three cell lines derived from EBV-positive BLs (Namalwa, Eli and
Akata 6) and two early passage LCLs (CH and Otis) that were
compared with two late passage LCLs (IB4 and X50-7). The
results are shown in Figure 10B. There was a trend in all the cell
lines for the distribution of these epigenetic marks to be non-
random. In general, the maximum amounts of both H3K27-Me3
and CpG methylation were associated with the loci amplified by
primer sets C and D. Consistent with all the preceding data, cells
expressing the EBV latency III pattern exhibited a significantly
higher level of H3K27-Me3 than the EBV-negative and type I
latency cells. The only anomaly was Eli, that was confirmed by
western blotting to have retained its latency I phenotype (Figure
S2D), but shows relatively high levels of H3K27-Me3 on the Bim
promoter. One of the most striking observations from this series of
experiments was that – as we saw using two other assays for CpG
methylation (MSP and bisulphite sequencing) – in early passage
LCLs (CH and Otis) the amount of DNA methylation on the Bim
promoter was low. In contrast analysis of both late passage LCLs
(IB4 and X50-7) showed Bim has become heavily methylated.
Since Bim expression is similarly low in both early and late LCL
cells, the repression of Bim transcription in LCL-CH and LCL-
Otis is almost certainly associated with the very high levels of
H3K27-Me3 distributed across the promoter region. The data are
again consistent with the hypothesis that H3K27-Me3 on Bim
precedes, and may then be replaced by the more stable epigenetic
mark, DNA methylation.
Discussion
EBV represses the expression of Bim in human B cells [4,13,16]
and this study has revealed a remarkable correlation between
latent infection of B cells with this gammaherpesvirus and
repressive epigenetic marks on the chromatin of the Bim gene
promoter. Bim is a highly regulated inducer of apoptosis, the level
of which is a critical rate-limiting factor in B cell survival [5]. It is
often deleted in mantle cell lymphoma [43] and in an Em-myc
transgenic mouse model it is a haploinsufficient tumour suppressor
[7] indicating that very modest changes in the amount of Bim in a
B cell can have profound effects on its survival and the
development of neoplasia. Bim levels are therefore finely regulated
by modulation of transcription and modulation of both mRNA
and protein stability (see Introduction). Recently Bim mRNA has
also been identified as a target of the potentially oncogenic miR-32
and miR-17-92 microRNA clusters [44,45,46,47].
Although it has been appreciated for several years that latent
infection with EBV can produce a dramatic reduction in the
amount of Bim expressed in B cells, at the onset of this study it
remained unclear at precisely what level and by what molecular
mechanism EBV regulates Bim expression. By demonstrating that
EBV infection leads to a significant down-regulation of Bim
mRNA levels and that the reduction in Bim protein does not
Figure 7. Bim promoter DNA is methylated in biopsies from EBV-positive BL. MSP was performed for DNA isolated from biopsy material, in
the same manner as with DNA from cell cultures (Figure 6 and Materials and Methods). In the matrix presented, the methylation state of the Bim
promoter is shown for the regions assessed with each of the 5 MSP primer sets used. CpG methylation is indicated with ‘‘M’’ in red boxes. The
unmethylated state is indicated with ‘‘U’’ in colourless boxes. The EBV status for each biopsy was determined by microscopy and EBER RISH and is
indicated on the right panel (see also Figure 8 for representative examples). In vitro methylated DNA (Meth) and primary cells (PBMCs and B cells)
were used as positive and negative controls respectively. Two EBV-negative, lymphoid infiltrates showed no evidence of DNA methylation by MSP at
the Bim promoter.
doi:10.1371/journal.ppat.1000492.g007
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appear to depend on ERK signalling [4], proteasome function or
changes in Bim mRNA turnover (this study), we have focused
attention on Bim transcription as the primary target of EBV.
Consistent with these observations, EBV-mediated repression of
Bim was shown to be associated with reduced acetylation on
histones H3 and H4. Moreover Bim expression in EBV-infected
cells was sensitive to agents that inhibit the maintenance of
epigenetic marks on the histone and DNA components of
chromatin. Taken together these results indicate that EBV
primarily regulates the expression of Bim by reducing the rate of
transcription through epigenetic mechanisms that may be initiated
and/or maintained by the functional interaction of EBNA3A and
EBNA3C [4].
Epigenetic modifications change chromatin structure without
altering DNA sequence and they modify gene expression in a
heritable manner. There are two closely linked components of the
epigenome – methylation of cytosine in CpG dinucleotides and
covalent modifications to the N-terminal tails of histones that alter
chromatin organisation and function. Combined, these modifiers
of gene expression can facilitate the long-term repression or
Figure 8. DNA methylation analysis of the Bim promoter by MSP and bisulphite sequencing in two EBER-positive BL biopsies. A)
EBER RISH was performed to confirm the presence of EBV in tumour material. Cells staining brown-pink are positive for EBER RNA. B) MSP was
performed for DNA isolated from the biopsies, in the same manner as with DNA from cell cultures (Figure 6 and Materials and Methods). Amplified
DNA was visualized by agarose gel electrophoresis, for all primer sets (I–V), with primer sets specific for unmethylated state (U) or methylated state
(M). C) Bisulphite sequencing was performed on DNA from these two EBV-positive biopsies to study DNA methylation at higher resolution. The
results of sequencing DNA from PBMC and BL2 are shown in the bottom two panels for comparison.
doi:10.1371/journal.ppat.1000492.g008
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silencing of genes [28,34]. Changes in epigenetic marks –
particularly regional gains in CpG methylation associated with
the silencing of tumour suppressor genes – are common in most
cancers [27]. Recently there has been speculation that infectious
agents may induce epigenetic modifications that could contribute
to the development of human tumours or other chronic conditions
([48] and see below). It is generally concluded that epigenetic
repression is progressive and is probably initiated by preventing
activation and removing the acetylation marks on histones that
ensure chromatin has an ‘open’ active configuration. This is
followed by covalent attachment of repressive marks on histones
and subsequently promoter DNA methylation [28,34,35]. In the B
cells we have investigated here, it is probable that EBV has
inhibited the transcription of Bim – via a mechanism involving
EBNA3A and 3C and repressive marks on local chromatin – and
prevented the efficient assembly of transcription complexes at or
around the transcription initiation site. This then made the
unusually large CpG-island available for DNA methylation. The
demonstration that DNA methylation is probably a relatively late
event after infection with EBV prompted us to investigate a
histone modification associated with transcriptional repression.
Trimethylation on lysine 27 of histone H3 has been shown in
cancer cells to be a precursor to CpG methylation on DNA
([38,39,40,41], reviewed in [42]). H3K27-Me3 of Bim occurs in
low passage LCLs and in vitro ‘converts’, and this modification then
creates an ideal substrate for the natural selection of the more
stable epigenetic mark DNA methylation. These data provide
compelling support for a model for EBV-associated lymphoma-
genesis that involves virus induced epigenetic reprogramming.
Currently we do not know precisely where or how H3K27-Me
and CpG methylation are ‘seeded’ or the rate or mechanism of
spread or even whether we have focused on the functionally
important nucleotides in the CpG island. Nor do we understand
the roles of EBNA3A and EBNA3C in the process. Nevertheless,
since presently the only known cellular histone methyltransferase
(HMT) capable of methylating H3K27 is a polycomb group (PcG)
protein called EZH2 [42] then it is tempting to speculate that EBV
may be utilizing the PcG family of chromatin regulators to
suppress expression of Bim. Whatever the mechanisms, we suggest
that spread of DNA methylation and stable repression would be
driven, at least in BL, by the strong selection pressure to prevent
Bim-mediated apoptosis induced by deregulated Myc [10,11].
In summary, we propose that when EBV infects naive B cells
and type III latency is established, that Bim is down-regulated
through the actions of EBNA3A and EBNA3C and that this is
necessary because EBNA2 activates Myc, which would otherwise
induce an increased amount of Bim and apoptosis (see [4,49]).
This involves epigenetic changes on the Bim promoter that may
prevent its activation by deregulated Myc and reduces the
expression of Bim below a critical threshold. Thus Myc activation
by EBNA2 – or a translocation event as is found in all BL – can be
tolerated in an EBV-infected B cell. The initial epigenetic marks
on Bim make the CpG-island available for DNA methylation
capable of reinforcing the inhibition of transcription. By definition
epigenetic changes will be inherited by progeny cells and during
the pathogenesis of EBV-positive BL there will be continuous
selection pressure to ensure that the suppression of Bim is retained.
Moreover EZH2, the histone methyltransferase responsible for the
H3K27-Me3 mark, can specifically recruit DNA methyltransfer-
ases (DNMTs) and so accelerate local CpG methylation [38]. This
will continue to be the case after the proteins that initiated the
reduction of transcription are no longer expressed in the EBNA1-
only type I latency characteristic of BL [3].
To our knowledge EBV encodes no DNMTs but we cannot rule
out interactions between EBV factors and cellular DNMTs
(similar to those reported for KSHV LANA1 protein and the
papillomavirus nuclear oncoproteins) being involved in the
targeted repression of Bim (see [50,51]). The recent discovery that
KSHV, via the LANA1 protein, can down-regulate expression of
the TGFb-type II receptor and initiate methylation of its promoter
[52], suggests that epigenetic modification of the host genome by
viruses capable of a latent infection could be a common feature
during disease pathogenesis. At this stage direct interactions
between EBV factors and PcG proteins should not be excluded.
Finally it should be noted that screens for promoter methylation
in a variety of other cancers (including breast and ovarian) have
revealed no significant or consistent methylation of the Bim
promoter using the same MSP primer sets as those used in this
study (PS – unpublished data). Furthermore we have seen no
consistent down-regulation of any other BH3-only pro-apoptotic
proteins (including Bid, Noxa or Puma) in EBV-positive relative to
EBV-negative B cells (our unpublished data). It is interesting to
note that CpG methylation of Puma was recently demonstrated in
Myc-driven B cell lymphomas – including some BL – but this was
not dependent on infection with EBV and may even be absent in
cells expressing the latency III pattern of EBV genes [53].
Supporting Information
Figure S1 Degradation of Myc and b-Actin mRNAs following
treatment with actinomycin D. A similar experiment to that shown
in Figure 1B was done to test mRNA degradation rates of a rapidly
degraded mRNA–Myc–and a slower degraded mRNA–b-Actin,
as controls. In the top graph the rate of Myc mRNA degradation is
shown. The rate of degradation appears greater for Myc mRNA,
relative to Bim mRNA, as expected. In the second graph the rate
of degradation of b-Actin mRNA is shown. This is slower than
both Myc and Bim mRNA, as expected. After the first hour of
treatment with Act D, the levels of b-Actin mRNA seems to go
down faster in uninfected cells, relative to infected ones. Because a
Figure 9. Increased levels of H3K27-Me3 along the Bim
promoter in EBV infected cells. ChIPs were performed to study
the occupancy of histone H3, trimethylated at K27, on the Bim
promoter, relative to EBV status. The occupancy for BL31 and BL41 cells,
infected with EBV or left uninfected are shown. Six primer pairs (A–F)
were used corresponding to sites across the promoter/CpG-island
region (see Figure 2 for locations). For each primer pair immunopre-
cipitated DNA associated with H3K27-Me3 was assessed by quantitative
PCR and is expressed in the graph as fold enrichment relative to input
chromatin. Trimethylated histone H3 at K27 is more abundant on the
Bim promoter of EBV infected cells.
doi:10.1371/journal.ppat.1000492.g009
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Figure 10. H3K27-Me3 and DNA methylation profiles along the Bim promoter. A) Schematic showing the analysis strategy. Chromatin and
isolated DNA were sonicated and used for precipitation of either DNA associated with H3K27-Me3 or methylated DNA. The same 6 pairs of primers
specific for loci spanning the Bim promoter (A–F, see Figures 2 and 9) were used to assess both H3K27-Me3 and DNA methylation in different cell
lines. The correlation between these two epigenetic marks could thus be followed across the promoter region as indicated. B) BL41, infected with
EBV or uninfected, latency III Namalwa, latency I Eli and Akata 6, early LCLs CH and Otis, and late LCLs IB4 and X50-7 were studied. The bars represent
fold enrichment for co-precipitated DNA relative to input chromatin/DNA into each precipitation, as determined by quantitative PCR. The height of
the bars is representative of the abundance of each epigenetic mark at the locus assessed by each primer set. The absolute abundance cannot be
compared between the different epigenetic marks, because different precipitation methods were used (see Materials and Methods section).
However, the trends for each mark across the promoter and between cell lines could be assessed.
doi:10.1371/journal.ppat.1000492.g010
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constant amount of RNA was used to assess Bim mRNA levels at
each time point, this is probably due to uninfected cells dying
faster than infected ones, and faster than the normal turnover of b-
Actin mRNA. Hence, the levels of b-Actin mRNA follow the rate
of cell death, in this case. The relative amount of mRNAs in these
cells at the start of the treatment is shown in the bottom graph.
Found at: doi:10.1371/journal.ppat.1000492.s001 (1.65 MB TIF)
Figure S2 Inhibitors of HDACs and DNMTs up-regulate Bim
protein levels in EBV infected cells (without inducing the lytic
cycle) in in vitro converts and latency I cells. A) EBV-negative BL
lines BL41 and Ramos and EBV-positive BL41 and Ramos AW
were treated with TSA, AZA and Na But. Bim protein levels were
assessed by western immunoblotting. In EBV-positive cells there is
a slight increase of Bim levels, especially after treatment with TSA
and Na But as in Figure 3. B) Latency I Eli and Akata 6 cells were
treated with TSA and AZA. Bim protein levels increase slightly,
especially after AZA treatment. C) To test whether treatment with
these drugs induced the EBV lytic cycle, and in this way possibly
affect Bim expression, the level of transcriptional activator of lytic
genes BZLF1 was assessed by western immunoblotting. BZLF1
was not present at higher levels in BL31 cells infected with EBV
(BL31 WT) or LCL CH cells after treatment with these inhibitors.
This suggests that the lytic cycle was not induced by the
treatments. BL31 E2KO cells have increased BZLF1 levels after
TSA treatment and they were used as positive control. D) To
verify that cell lines considered to have the latency I expression
pattern had not ‘drifted’ to latency III, western immunoblots were
performed to assess EBNA3A and EBNA3C expression. The
EBV-negative cell line BL31 and latency I Eli, Akata 6 and Dante
cell lines did not have detectable levels of either protein, indicating
that these latency I cell lines had not significantly ‘drifted’ to
latency III.
Found at: doi:10.1371/journal.ppat.1000492.s002 (2.77 MB TIF)
Figure S3 MSP analysis of cell lines. Amplified DNA by MSP
was visualized by agarose gel electrophoresis, for all primer sets (I–
V), with primer pairs specific for unmethylated state (U) or
methylated state (M). Here, as a representative example, the results
for cell lines with primer set III are shown to demonstrate how
these were interpreted to produce the matrix in Figure 5. DNA
from primary B cells was used as a negative control for DNA
methylation and in vitro methylated Jurkat DNA (Meth) as a
positive control.
Found at: doi:10.1371/journal.ppat.1000492.s003 (1.76 MB TIF)
Figure S4 MSP analysis of DNA from biopsy samples. To
demonstrate how MSP data were produced for presentation in the
matrix in Figure 7, DNA amplified by MSP using each set of
primers (I–V) and visualized by agarose gel electrophoresis is
shown. For each primer set, primer pairs specific for unmethylated
state (U) or methylated state (M) were used. DNA from primary B
cells was used as a negative control for DNA methylation and in
vitro methylated Jurkat DNA (Meth) as a positive control.
Found at: doi:10.1371/journal.ppat.1000492.s004 (2.40 MB TIF)
Figure S5 Controls for methylated DNA precipitations. Precip-
itations were performed as described in Figure 10A using DNA
extracted from PBMCs (as a control for unmethylated DNA and
DNA (Meth) from Jurkat cells methylated in vitro [(Meth) as a
control for fully methylated DNA]. There is no DNA methylation
at the Bim promoter of PBMCs and no enrichment was observed.
For in vitro fully methylated DNA, the enrichment observed was
determined by the concentration of CpG dinucleotides at the locus
assessed by the particular primer pair. For primer pair A, which is
outside the CpG-island, there was no significant enrichment.
There was also no DNA precipitated when only the magnetic
beads were used, without the His-MBD2b protein attached.
Found at: doi:10.1371/journal.ppat.1000492.s005 (1.53 MB TIF)
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